Completed Enrollment

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

I8F-MC-GPIQ -

The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Obesity, Overweight
What the trial is testing?
Tirzepatide (LY3298176)
Could I receive a Placebo?
Yes
Enrollment Goal
400
Trial Dates
Sep 20, 2023 - May 2026
How long will I be in the trial?
The study will last approximately 112 weeks and include up to 26 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have obesity

  • Have overweight with at least one:

    • obstructive sleep apnea

    • Have high blood pressure

    • Have high cholesterol

    • Have heart disease

Participants Must Not:

  • Have type 1 or type 2 diabetes

  • Have a self-reported change in body weight over 5 kg within 3 months before screening

  • Have a planned or prior surgery for obesity

  • Have “severe” kidney impairment

  • Have long-term or short- term inflammation of the pancreas

  • Have used GLP-1 receptor agonist within 12 months before screening

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources